Phase 3 N=416 PCM Cervical Disc System
Radiculopathy · Myelopathy
Primary: Individual Patient Overall Success — 142; 98 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,262 A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24 — 69.4; 73.4 Percentage of participants
Phase 3 N=157 Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
Prostate Cancer
Primary: Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196 — 96.7 percent probability
Phase 3 N=657 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Leukemia
Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months
Phase 3 N=124 Treatment of Obsessive Compulsive Disorder in Children
Obsessive-Compulsive Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 0.69; 0.34; 0.30 Proportion of Participants with RESPONSE
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Phase 3 N=583 A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
Epilepsy
Primary: Percentage of Participants Who Experienced Seizure Freedom for 26-weeks During the Maintenance Phase — 79.4; 83.7 Percentage of Participants
Phase 3 N=352 An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
Diabetic Neuropathy
Primary: Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT) — -2.22; -1.73; -1.30; -1.85 Scores on a Scale
Phase 3 N=742 A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1 — 0.8; 1.6; 9.5; 10.5 percentage of participants
Phase 3 N=262 Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
Neuralgia
Primary: Mean Change From Baseline in Short Form-McGill Pain Questionnaire (SF-MPQ): Sensory and Affective Scores, From Baseline to Week 48. — -10.5; -8.1; -9.0; -9.8 Scores on a…
Phase 3 N=205 Telemonitoring Versus Usual Care
Health Care Quality · Health Care Access
Primary: Mean # Participants Who Had Hospitalizations or ED Visits Compared to Usual Care in a High Risk Group of Adults ≥ 60 Years of Age With Mixed Chronic Disease. — 65; 59…
Phase 3 N=604 BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
Obesity
Primary: Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52 — 37.5; 44.7; 16.1 percentage of participants…
Phase 3 N=707 Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Primary Insomnia
Primary: Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO) — 85.0; 86.6; 92.3; 76.5 minutes — p=<0.0001
Phase 3 N=3,182 BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
Obesity
Primary: Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52 — 47.5; 20.3 percentage of participants — p=<0.0001
Phase 3 N=4,008 BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
Obesity
Primary: Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52 — 40.2; 47.2; 25.0 percentage of participants…